Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Impact of the PROactive Study on the Treatment of Type 2 Diabetes

Published by: Decision Resources

Published: May. 2, 2006 - 20 Pages

Price reduced due to age.

Table of Contents


Contents Introduction: Promising Results in the Recent PROactive Study

Type 2 Diabetes: Disease Background and Prevalence

Pathophysiology and Risk Factors

Type 2 Diabetes and Cardiovascular Disease

Prevalence of Type 2 Diabetes

Overview of Current Drug Therapies

Sulfonylureas

Meglitinides

Alpha-Glucosidase Inhibitors

Biguanides

Peroxisome Proliferator-Activated Receptor-Gamma Agonists

Glucagon-Like Peptide-1 Analogues

Amylin Analogues

The PROactive Study: Revealing a Potential Breakthrough Treatment for Cardiovascular Disease in Type 2 Diabetes

The Role of PPAR in Cardiovascular Disease

PROactive Study Design

PROactive Study Results

Shortcomings of the PROactive Study

Outlook

Figure 1 Onset and Complications of Type 2 Diabetes

Table 1 U.S. and Worldwide Sales of Select Antidiabetic Agents, 2005

Figure 2 Mechanism of Action for PPAR-? Agonists in Type 2 Diabetes

Table 2 Number of Patients Using Concomitant Medication During the PROactive Study

Table 3 PROactive Trial: Summary of the Effects of Pioglitazone on the Study Parameters

Figure 3 Sales Growth of Antidiabetic Drug Classes, 2000-2004

Abstract

The life-threatening complications of type 2 diabetes constitute a significant unmet medical need worldwide, particularly because the prevalence of type 2 diabetes has soared in recent years as a result of changing eating habits and lifestyles. The current selection of antidiabetic drugs successfully manage the disease, but until the late 2005 release of results from the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) study, no data quantified the effects of antidiabetic drugs on the incidence of cardiovascular disease (CVD). While the results of the PROactive study suggest that pioglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, may mitigate the occurrence of cardiovascular events in type 2 diabetes patients with a history of CVD, certain aspects of the PROactive study have been a cause for concern among members of the medical community. This report discusses the PROactive study, beginning with an overview of type 2 diabetes, including information on its increasing prevalence and associated comorbidities, particularly cardiovascular complications, and available therapies. Next, we discuss pioglitazone’s pharmacological profile as well as the design, results, and possible shortcomings of this breakthrough trial. Finally, we forecast the potential effect of the PROactive study on sales of pioglitazone and the commercial opportunities for other antidiabetic agents.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008